ICER assessed GSK's COPD inhalers, Trelegy Ellipta and Breo Ellipta, for Medicare price negotiations, highlighting their once-daily dosing and comparable net health benefits.

The higher prices of two COPD inhalers from GSK that are targeted in the second round of government drug price negotiations ...

The Institute for Clinical and Economic Review has prepared a special report on Trelegy and Breo, two therapies that treat ...

The shares of Senores Pharmaceuticals Limited were trading at ₹570.70 up by ₹36.90 or 6.91% on the NSE today at 2.32 pm.

A new study published in the CHEST journal found that ensifentrine, an innovative inhaled therapy, significantly reduces the ...

A multimodal, digital community-based intervention was feasible and decreased illness-related distress in treating patients ...

Vantage Market Research is pleased to announce the publication of its latest report, Asthma and COPD Drugs Market. This ...

GSK (GSK) announced that the China National Medical Products Administration, CNMPA, has accepted for review the new drug application for the ...